The RDCRN program is designed to advance medical research on rare diseases. It facilitates clinical research in rare diseases. Read the latest news about this program below.
New Funding Opportunities Available for Collaborative Rare Diseases Research
NCATS has released two new RDCRN funding opportunities to support collaborative clinical research on rare diseases. Applications for Rare Diseases Clinical Research Consortia and a Data Management and Coordinating Center are due by Oct. 9, 2018.
NIH-Supported Scientists Discover New Personalized Approach to Diagnosing and Treating Rare Food Allergy Disease
With RDCRN support, a team of scientists from Cincinnati Children’s Hospital Medical Center and the Consortium of Eosinophilic Gastrointestinal Disease Researchers has developed a new personalized approach to diagnosing and treating a rare food allergy disease called eosinophilic esophagitis.
NIH-Supported Research Helps Advance a Potential Rare Disease Gene-Editing Treatment into Clinical Trials
RDCRN-supported research helps chart how several rare, inherited disorders progress in patients over time. This information facilitated the advance of a potential rare disease gene-editing treatment into clinical trials.
NCATS-Supported Consortium Charts New Course for Rare Immune Diseases
Scientists with an NCATS-supported research consortium are pioneering new studies to better understand and develop therapies for rare immune system disorders. The Primary Immune Deficiency Treatment Consortium conducts natural history studies and other research as part of the NCATS Rare Diseases Clinical Research Network.
Unprecedented Trans-NCATS Collaboration Enables Rapid Advancement of Rare Lung Disease Therapy to Human Trials
aPAP is a rare lung disease with a difficult treatment. With this collaboration, Dr. Trapnell is optimistic that a potentially life-changing treatment is one step closer to benefiting patients.
Breathing Easier: First Treatment for Rare Lung Disease Approved
Research coordinated by The LAM Foundation and carried out with scientific partners in NCATS’ Rare Diseases Clinical Research Network culminated in the first treatment for lymphangioleiomyomatosis (LAM) approved by the Food and Drug Administration.
Patients with Rare Muscle Disorder Benefit from Repurposed Heart Drug
With RDCRN and CTSA Program support, researchers at seven institutions in four countries were able to recruit enough patients with a rare genetic muscle disorder for a clinical trial to test a potential repurposed drug therapy called mexiletine, normally prescribed for heart disorders.